Vanda Pharmaceuticals Launches Nereus, First New Motion Sickness Treatment in 40 Years
VNDA sits 93% above its 52-week low of $3.809 on light trading volume (0.3× avg).
Summary
Vanda Pharmaceuticals announced the U.S. commercial availability of Nereus (tradipitant) for motion sickness, marking the first new pharmacologic treatment for the condition in over 40 years. The drug will be accessible via a direct-to-consumer platform at a cash-pay price of $85 per dose, with a standard list price of $255. This launch represents a significant new revenue opportunity for Vanda, especially given the company's reported increased net losses and regulatory setbacks for other drug candidates in its last 10-K. Traders will closely monitor initial sales performance and market adoption to gauge the financial impact of this novel product on the company's future outlook.
At the time of this announcement, VNDA was trading at $7.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.8M. The 52-week trading range was $3.81 to $9.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.